Psychotropic Research Articles

Maternity and motherhood in street situation: integrative review.

The objective was to identify through integrative review the approach on maternity and motherhood in street situation. This is an integrative review performed in the databases PubMed, BIREME, Medline, and SciELO search portal, in Portuguese, English and Spanish. The survey was conducted between October and December 2021, following the recommendations of the Prisma flowchart and support of the Mendeley software, submitted to content analysis by Minayo. Eighteen articles were selected. The reading allowed the identification of two thematic categories: "Maternity and mothering in the streets" and "Main challenges experienced in maternity and mothering in street situation". Address about motherhood and mothering as a field of knowledge production creates a tension of the social constructions that do not have effecting rights for lack of programs and forceful intersectoral policies. In addition to the stigmatization for use of psychoactive substances, as well as the patriarchal structure attributed to motherhood. The responsibility for care entails several issues that cross the motherhood and mothering in the streets, namely: concern with the health of children, the fear of losing custody of their loved ones.

Prediction of Utilization of Psychological Support During Vocational Rehabilitation

Comprehensive psychological support is a distinctive feature of vocational retraining centers, pivotal in stabilizing the health of the rehabilitants, reducing dropout rates and facilitating return to work. For optimal resource planning within the vocational retraining centers, and thereby ensuring the best possible psychological support during vocational rehabilitation, it is crucial to be able to estimate the number of appointments of the rehabilitants in advance. Even though routine data is available, predictions using regression analysis have not been undertaken previously. To predict the number of appointments in the psychological service, a hierarchical linear regression analysis with 25 potential predictors was conducted using retrospective routine data from 404 rehabilitants. In specifying the regression model, data-driven methods and theory were combined. The Andersen healthcare utilization model served as the theoretical background. The final regression model accounted for 39.5% of the variance in the utilization of the psychological service. Ten variables predicted a higher number of appointments: female gender, boarding status, low resilience, desire for psychological support, past psychological treatment, intake of psychotropic drugs, absence of two specific professional fields, Federal Employment Agency/Jobcenter as the paying institution, and non-participation in a specific preparatory course. The routine data available at the beginning of vocational rehabilitation in a vocational retraining center is generally suitable to predict the number of appointments in the psychological service. As such, it can be utilized for resource planning. Various factors prove to be informative, suggesting that a focus on single factors (e. g., the presence of an ICD-10 F-diagnosis) seems disadvantageous. Limitations of the regression-analytic approach are highlighted.

Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review.

Since 2003, the Food and Drug Administration (FDA) has warned that antidepressants may be associated with suicidal thoughts and behaviors among youth. An FDA advisory in 2003 and a black-box warning in 2005 focused on children and adolescents younger than age eighteen. The FDA expanded the black-box warning in 2007 to include young adults. Both warnings were intended to increase physician monitoring of suicidal thoughts and behaviors. Our systematic review identified thirty-four studies of depression and suicide-related outcomes after these warnings; eleven of these studies met research design criteria established to reduce biases. The eleven studies examined monitoring for suicidal thoughts and behaviors, physician visits for depression, depression diagnoses, psychotherapy visits, antidepressant treatment and use, and psychotropic drug poisonings (a proxy for suicide attempts) and suicide deaths. We assessed possible spillover to adults not targeted by the warnings. The one study that measured intended physician monitoring of suicidal thoughts and behaviors did not find evidence of an increase. Multiple studies found significant unintended reductions in mental health care after the warnings. After these reductions, there were marked increases in psychotropic drug poisonings and suicide deaths. These findings support reevaluation of risks and benefits of the FDA's black-box antidepressant warnings.

Chronic olanzapine treatment leads to increased opioid receptor expression and changes in feeding regulating neurons in the female rat hypothalamus

Opioid receptor antagonists have shown increasing promise as an adjunct therapy to psychotropic medication. The goal is to reduce the weight gain and metabolic adverse effects that are associated with certain second-generation antipsychotics, such as olanzapine and clozapine. In this study, female rats were treated for 4 weeks with a long-acting injectable formulation of olanzapine to assess effects on hypothalamic feeding regulation. Using quantitative spatial in situ hybridization and receptor autoradiography, expression levels of the mu, kappa and delta opioid receptors were defined in the five hypothalamic areas: paraventricular nucleus (PVN), arcuate nucleus (ARC), ventromedial nucleus (VMN), dorsomedial nucleus (DMN) and lateral hypothalamus (LH). In addition, hypothalamic neuron number and size were estimated using the unbiased optical fractionator and spatial rotator methods. Hyperphagia was observed after only 24hours of olanzapine treatment, with continued weight gain throughout the duration of the study. In contrast, the observed food intake reversed to control levels after 2 weeks of olanzapine treatment. Chronic olanzapine treatment increased expression of kappa opioid receptor mRNA and receptor availability in the PVN, as well as increased mu opioid receptor availability in the PVN, ARC and VMN. These changes were accompanied by fewer anorexigenic proopiomelanocortin-expressing neurons of the ARC and corticotropin-releasing hormone expressing neurons of the PVN. This study links olanzapine-driven metabolic effects to increased opioid receptor expression in the hypothalamus, thus providing a rationale for the positive effects of using opioid receptor antagonists to relieve olanzapine adverse effects.

The TMEM132B-GABAA receptor complex controls alcohol actions in the brain.

Alcohol is the most consumed and abused psychoactive drug globally, but the molecular mechanisms driving alcohol action and its associated behaviors in the brain remain enigmatic. Here, we have discovered a transmembrane protein TMEM132B that is a GABAA receptor (GABAAR) auxiliary subunit. Functionally, TMEM132B promotes GABAAR expression at the cell surface, slows receptor deactivation, and enhances the allosteric effects of alcohol on the receptor. In TMEM132B knockout (KO) mice or TMEM132B I499A knockin (KI) mice in which the TMEM132B-GABAAR interaction is specifically abolished, GABAergic transmission is decreased and alcohol-induced potentiation of GABAAR-mediated currents is diminished in hippocampal neurons. Behaviorally, the anxiolytic and sedative/hypnotic effects of alcohol are markedly reduced, and compulsive, binge-like alcohol consumption is significantly increased. Taken together, these data reveal a GABAAR auxiliary subunit, identify the TMEM132B-GABAAR complex as a major alcohol target in the brain, and provide mechanistic insights into alcohol-related behaviors.

Long-term opioid prescribing and the incidence of opioid-related hospitalizations or emergency department visits among patients with metastatic cancer.

200 Background: Many patients with metastatic cancer experience cancer-related pain which is commonly managed using opioids. Although opioids are an effective tool for cancer pain management, their use can result in adverse effects which may be related to long-term use and are understudied in this population. Therefore, we aimed to describe long-term opioid prescribing (LTOP) practices among patients with metastatic cancer and investigate the incidence of opioid-related hospitalizations and emergency department (ED) visits among recipients of long-term prescribing. Methods: This retrospective cohort study used population-based data from Alberta, Canada to identify patients diagnosed with stage IV cancers between 2004-2017 who had at least 1-year of follow-up and were opioid naïve at diagnosis. LTOP was defined as receipt of a ≥90-day supply of opioids with less than a 30-day gap in supply within a 180-day period. Prescribing practices were characterized according to timing (early vs. end-of-life [EoL] onset), morphine equivalent dose, duration, and concurrent medication use. The EoL phase of disease was defined as the year preceding death. The incidence rate of opioid-related encounters was compared between different characteristics of LTOP. Results: The study included a total of 10927 patients, 2521 (23%) of whom received long-term opioid prescribing after diagnosis. LTOP became more common as patients approached EoL, with most patients (53%) having LTOP initiated only within their last year of life. 85 patients (3.4%) experienced an opioid-related hospitalization or ED visit after initiation of LTOP, with an incidence rate of 2.36 (95% CI 1.92, 2.86) encounters per 100 person-years. Higher opioid dosage and concurrent prescribing of anxiolytics, benzodiazepines, antidepressants, and neuroleptic medications were significantly associated with a higher incidence of opioid-related encounters. Conclusions: Long-term opioid prescribing is commonly experienced by patients living with metastatic cancer as a chronic disease. The concurrent use of psychoactive drugs during LTOP was associated with experiencing opioid-related hospitalizations/ED visits.

Effects of repeated voluntary oral consumption of synthetic delta-9-tetrahydrocannabinol on locomotor activity and cannabinoid receptor 1 expression

As cannabis legalization expands, preclinical studies continue to investigate the impact of repeated exposure to delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in the plant. With the increasing popularity of cannabis infused foods, the rise of THC in medicinal applications have also expanded. The present study addresses a critical gap in existing literature by investigating the behavioral and neurobiological effects of low-dose edible THC in a preclinical rodent model. Adult male rats were administered synthetic-THC (Dronabinol) (0.0625mg/kg, 0.125mg/kg, and 0.25mg/kg) or vehicle (sesame oil) through edible cookies, 90min prior to eight locomotor sessions. Locomotor activity significantly increased in both 0.0625mg/kg and 0.25mg/kg THC groups, indicating a dose-dependent relationship. Repeated 0.25mg/kg THC administration dose-dependently reduced cannabinoid receptor 1 expression in the hippocampus. The observed neurobiological change from low dose oral THC advances our understanding of repeated cannabis use. These findings also emphasize the importance of refining rodent models for translational relevance.

Microelimination of Hepatitis C in Patients with Substance Use and Dual Disorders - a Portuguese Study.

Chronic hepatitis C (CHC) is a serious condition of public health importance. In Portugal, the prevalence of detectable hepatitis C virus (HCV) antibodies is approximately 0.54%, with a higher prevalence in high-risk groups. Compared with the general population, the prevalence of HCV infection is higher in individuals with psychiatric disorders. As no studies have reported the prevalence of HCV antibodies in Portuguese patients with psychiatric conditions and substance use disorders, we conducted an observational, prospective study of patients followed in the Dual Pathology Outpatient and Inpatient Unit of Coimbra Hospital and University Center (CHUC), Patients were tested for HCV antibodies. Of the 149 patients, 17.4% were positive for HCV antibodies and 7.4% had detectable HCV RNA indicating CHC. Most patients with confirmed CHC were male inpatients, aged 50 to 59 years, and reported unprotected sex with more than one concurrent partner in the past 6 months. Their most common psychiatric diagnosis was "Disorders due to use of multiple specified psychoactive substances, including medications." The prevalence of HCV antibodies and confirmed CHC were higher in patients followed in the Dual Pathology Outpatient and Inpatient Unit than in the general Portuguese population.

COMPARISON BETWEEN OLANZAPINE AND HALOPERIDOL AS TREATMENT OF ACUTE AGITATION

Introduction – Antipsychotics have been used as a treatment of choice in acute agitation, with haloperidol being the most widely used from the first generation, and olanzapine from the second generation. Therefore, there is a need to understand these drugs, particularly in their efficacy and safety as a treatment of acute agitation. Methods – This review uses several works of literature between 2011 to 2021 that discuss olanzapine and haloperidol as treatments for acute agitation. Results – Atypical antipsychotic agents are equally effective when compared to typical antipsychotics in treating acute agitation Discuss – On several head-to-head comparisons, olanzapine showed superiority to haloperidol based on the onset of efficacy. Conclusion – Agitated patients interfere with the diagnostic and treatment process. First-line treatment involves verbal de-escalation for patients and if failed, a physician could use pharmacological intervention in the form of rapid tranquillization to continue the therapeutic process. When determining which drug to use, a physician must consider both efficacy and safety. Due to the heterogeneity of study results, it is difficult to conclude that a certain agent is the best treatment for acute agitation. Olanzapine and haloperidol are equally effective antipsychotic agents in treating agitated symptoms. Olanzapine has numerous advantageous properties, including a lesser risk of causing extrapyramidal side effects that in turn can aggravate agitation, but the downside of olanzapine is that it is expensive and has limited availability compared to haloperidol. On the other hand, haloperidol, as a monotherapy or combination therapy either with an antihistamine-anticholinergic or benzodiazepine is a good alternative. Therefore, determining which agent to use should consider the comprehensive state of the patient, as is almost always the case when psychotropic medications are prescribed. Keywords: olanzapine, haloperidol, agitation.

Knowledge, Attitude, and Practice Patterns on Psychodermatology among Filipino Dermatologists: A Cross-sectional Study.

Psychodermatology is a field that focuses on the interaction of the skin and the mind. Psychodermatology patients are often challenging to manage because they often lack insight and are not amenable to psychiatric treatment or referral. Therefore, it is important that dermatologists become aware of the psychosocial impact of cutaneous disease and be knowledgeable in the fundamentals of psychodermatologic diagnosis and therapy. However, studies done in several countries report a general lack of perceived knowledge, awareness, and confidence in the management of psychodermatology disorders among dermatologists. This study aims to determine the knowledge, attitudes, and practices of Filipino dermatologists towards psychodermatology using a self-administered questionnaire. This is a mixed methods study using qualitative and quantitative measures. A self-administered questionnaire was validated and disseminated among the dermatologists in the country. Descriptive analysis was done. Of the 153 participating dermatologists, majority (70.59%) reported psychodermatologic patients comprised <10% of their practice. While more than half (56.2%) have a clear understanding of psychodermatology and are comfortable (57.52%) in approaching patients with these conditions, only 58 (37.91%) participants are able to demonstrate adequate knowledge on psychodermatology. Patients with primary psychiatric disorders are less frequently encountered than dermatologic disorders with psychiatric component or secondary psychiatric disorders. Most commonly prescribed medications are anti-histamines. Other psychotropic medications are rarely or never prescribed by the participants. All participants agree that psychodermatology is important in the practice of dermatology; 127 (62.1%) have attended at least one Continuing Medical Education (CME) on psychodermatology and 114 (74.51%) expressed willingness to attend CME training in psychodermatology. One hundred nine (71.24%) participants think that the best practice approach is a multidisciplinary approach to psychodermatology. The top recommendations for better healthcare delivery in psychodermatology were better access to mental health specialists (86.27%), more training opportunities and better training during residency (75.16%), and increase collaboration with psychiatrists (71.9%). The knowledge score was found to be associated with the duration of dermatology practice and attendance in CME proceedings but was not associated with the perceived adequacy of knowledge gained during training. Longer duration of practice may be associated with the knowledge score owing to the greater exposure to cases and more access to training opportunities. There are many challenges to providing psychodermatologic care in the Philippines but the positive attitude towards psychodermatology, coupled with increased access to education and training opportunities, and the multidisciplinary approach to these cases may improve the quality of dermatologic care that we provide.

Audit of Lithium Monitoring in a Mental Health for Older Persons (Dublin North City Central) Service

Abstract Background Lithium is a psychotropic medication used for the treatment of bipolar affective disorder and augmentation for treatment resistant depression. Lithium monitoring is essential due to the narrow therapeutic range of serum lithium and the potential for toxicity. Other medications with similar risk profiles, such as warfarin, have established monitoring programmes. Older adults receiving lithium therapy are at an increased risk of adverse events, given the prevalence of medical co-morbidities and changing pharmacokinetics. The authors of this audit identified the lack of formalized lithium monitoring programme in the Mental Health Service for Older Persons (MHSOP). The aim of this audit to compare monitoring practices in the MHSOP against the current gold standard Irish Medication Safety Network (IMSN) for Prescribing and Monitoring of Lithium Therapy. Methods A survey of all community medical charts identifying patients attending the service receiving lithium therapy was completed. Data collected pertained to diagnosis, treating consultant, lithium dose, if the patient received educational material, compliance with ECG and blood monitoring. Results The MHSOP active case load was 682 patients, 14 patients were prescribed lithium therapy. Cycle 1 of the audit demonstrated poor compliance of lithium monitoring against the gold standard. A lithium pack was inserted in patient files to prompt all clinicians to follow the recommended standardized monitoring of lithium therapy as per the IMSN guidelines. In cycle 2 of the audit there was an improvement in recording blood monitoring across the patient group. Conclusion The audit demonstrated improvement in compliance with international guidelines following the intervention. It was recommended that a formalized Lithium Clinic was a needed resource for the MHSOP. The lithium monitoring pack will continue to be added to clinical files, included in Non-Hospital Consultant (NCHD) induction and multi - disciplinary teaching sessions. It is proposed that the audit be repeated in one year to longitudinally assess compliance.

A Systematic Review of Delta-9-Tetrahydrocannabinol (∆9-THC) in Astrocytic Markers.

Astrocytic reactivity in substance use disorders (SUDs) has been extensively studied, yet the molecular effect of delta-9-tetrahydrocannabinol (∆9-THC, the main psychoactive compound in cannabis) on glial cells, especially astrocytes, remains poorly understood. Exploring ∆9-THC's impact on astrocytic markers can provide insight into its effects on brain functions such as homeostasis, synaptic transmission, and response to neuronal injury. This systematic review synthesizes findings from studies investigating ∆9-THC's impact on astrocytic markers. A systematic review was conducted using EMBASE, Medline, and PsychoInfo via the OvidSP platform. Studies reporting astrocytic markers following ∆9-THC exposure in animals and humans were included. Data were extracted from twelve eligible full-text articles, and the risk of bias was assessed using the Systematic Review Center for Laboratory Animal Experimentation. This research identified several astrocytic markers, including glial fibrillary acidic protein (GFAP), nestin, and glutamate-aspartate transporter (GLAST). Both GFAP and nestin expressions increased in adulthood following adolescence and adult ∆9-THC exposure. An increase in GLAST expression was also noted during early development after ∆9-THC exposure. This review indicates varying levels of astrocytic reactivity to ∆9-THC across different developmental stages, including adolescence and adulthood. ∆9-THC appears to impact maturation, particularly during early developmental stages, and exhibits sex-dependent effects.

Synaptic basis of rapid antidepressant action.

The discovery of ketamine's rapid antidepressant action has generated intense interest in the field of neuropsychiatry. This discovery demonstrated that to alleviate the symptoms of depression, treatments do not need to elicit substantive alterations in neuronal circuitry or trigger neurogenesis, but rather drive synaptic plasticity mechanisms to compensate for the underlying pathophysiology. The possibility of a rapidly induced antidepressant effect makes therapeutic pursuit of fast-acting neuropsychiatric medications against mood disorders plausible. In the meantime, the accumulating clinical as well as preclinical observations raise critical questions on the nature of the specific synaptic plasticity events that mediate these rapid antidepressant effects. This work has triggered the current growing interest in alternative psychoactive compounds that are thought to have similar properties to ketamine and its action. This review covers our insight into these questions based on the work our group has conducted on this topic in the last decade.

Legal principles of evidence in criminal proceedings about organized groups and criminal organizations in the sphere of circulation of narcotic drugs, psychotropic substances or their analogues

Legal principles of evidence in criminal proceedings about organized groups and criminal organizations in the sphere of circulation of narcotic drugs, psychotropic substances or their analogues

Eu-MOF-based highly sensitive and selective luminescence probe for trace, in situ and visual detection of flunitrazepam

Flunitrazepam, as an emerging new psychoactive substance classified as a third-generation drug that is more harmful and camouflaged, is gradually proliferating globally. Maliciously used as a criminal tool in homicide and rape cases, it has already caused serious harm to public safety and social stability. Owing to its special molecular structure, low concentration level and rapid metabolic process in the human body, accurate detection of flunitrazepam remains a major challenge, especially for real sample and on-site detection. In this paper, a lanthanide MOF (Eu-MOF) based on bi-ligand was constructed as a luminescence probe and used for the first time to detect trace amounts of flunitrazepam. The ’antenna effect’ promotes strong luminescence of Eu-MOF, while the lower LUMO orbital energy level of flunitrazepam allows it to accept electrons from the electron donor leading to quenching of Eu-MOF luminescence. The probe has a high sensitivity and can detect flunitrazepam in the range of 0–800 μM with a detection limit as low as 73 nM. Moreover, flunitrazepam was detected in urine from real samples as well as in a variety of beverages to further validate its accuracy and practicality. The reported Eu-MOF represents one of the pioneering luminescence probes for the detection of flunitrazepam, which offers great promise for the on-site or on-line analysis of flunitrazepam.

Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study

BackgroundCurrent treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner.MethodsA retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. Patients aged more than 12 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP, had recorded of cannabis use in medical chart, and had positive urine test of cannabis on the first day of admission from October 2013 to September 2019 were enrolled. The primary outcome was the efficacy of pharmacological treatment of CIP. Brief Psychotic Rating Scale (BPRS) on the first day and weekly after receiving treatment were used to assess the primary outcome.ResultsFour hundred and three medical charts with diagnosis of CIP were enrolled into the study and only 317 charts were analyzed. Most of them were male with an average aged of 21.0 (19.0–24.0) years old. All of them used smoked cannabis from dried leaves and flowers of cannabis plant. The presented symptoms on admission were psychosis, mood symptoms, sleep problems, weight loss, and cognitive problems (100%, 64%, 61%, 11%, and 7%, respectively). Baseline BPRS score of the first day of admission was 55.2 ± 9.6. Majority of patients received antipsychotic (98.7%) followed by the combination of antipsychotics with benzodiazepines (34.5.%), antipsychotics with antidepressants (14.4%) and antipsychotics treatment with antidepressants and benzodiazepines (25.9%). Only few patients received antipsychotic monotherapy (17.9%). Risperidone was the most frequently prescribed antipsychotics (83.6%). Mean equivalence dose of risperidone was 8.0 ± 5.9 mg/day. The average hospital length of stay was 28 days (range 22-31). BPRS at 22 days significantly improved compared to the first day of admission (p < 0.001). Schizophrenia was diagnosed in 7% at 1.3 years of follow up.ConclusionAntipsychotics was still a key psychotropic drug for treatment of CIP. The symptoms were decreased rapidly and sustained among the treatment period. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychosis.Trial registrationClinicalTrials.gov ID: NCT04945031 (Registration Date: 30 June, 2021).

From fibers, to flowering, to metabolites: unlocking hemp (Cannabis sativa L.) potential with the guidance of novel discoveries and tools.

Cannabis sativa L. is an ancient crop whose agricultural adoption has been interrupted to prevent the use of marijuana as psychoactive drug. Nevertheless, hemp - the Cannabis sativa type with low concentrations of intoxicating Δ9-tetrahydrocannabinoid - is experiencing resurged interest thanks to loosened cultivation restrictions and its potential as multipurpose bio-based crop. In fact, hemp has valuable applications, including production of medicines from its non-intoxicating cannabinoids, food, medical, and industrial uses of its seed oil rich in poly-unsaturated fatty acids, and production of fibers for textiles and industry from its stems. Recently, several hemp genomic and genetic resources have been developed, allowing for a significant expansion of the genetic knowledge on major hemp traits, as cannabinoids, oil, and fibers synthesis, and regulation of flowering and sex determination. Still, hemp is an under-improved crop, whose advancement will depend on the ability to expand and collectively use the novel resources available in light of the fast advancements in bioinformatics and plant phenotyping technologies. This review discusses on the current genetic and genomic knowledge on the most important hemp traits, and provides a perspective on how to further expand such knowledge and tackle hemp improvement with the most up-to-date tools for plant and hemp research.

The Microbiota-Gut-Brain Axis and Neurological Disorders: A Comprehensive Review.

Microbes have inhabited the earth for hundreds of millions of years longer than humans. The microbiota-gut-brain axis (MGBA) represents a bidirectional communication pathway. These communications occur between the central nervous system (CNS), the enteric nervous system (ENS), and the emotional and cognitive centres of the brain. The field of research on the gut-brain axis has grown significantly during the past two decades. Signalling occurs between the gut microbiota and the brain through the neural, endocrine, immune, and humoral pathways. A substantial body of evidence indicates that the MGBA plays a pivotal role in various neurological diseases. These include Alzheimer's disease (AD), autism spectrum disorder (ASD), Rett syndrome, attention deficit hyperactivity disorder (ADHD), non-Alzheimer's neurodegeneration and dementias, fronto-temporal lobe dementia (FTLD), Wilson-Konovalov disease (WD), multisystem atrophy (MSA), Huntington's chorea (HC), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), temporal lobe epilepsy (TLE), depression, and schizophrenia (SCZ). Furthermore, the bidirectional correlation between therapeutics and the gut-brain axis will be discussed. Conversely, the mood of delivery, exercise, psychotropic agents, stress, and neurologic drugs can influence the MGBA. By understanding the MGBA, it may be possible to facilitate research into microbial-based interventions and therapeutic strategies for neurological diseases.

A comprehensive molecular analysis of cannabidiol: From solid state to antioxidant potential

Cannabis sativa contains approximately 540 natural compounds, including terpenes and flavonoids, and approximately 100 of these compounds are phytocannabinoids, of which the most studied are Δ9-tetrahydrocannabinol and cannabidiol. Due to potential therapeutic properties and psychoactive effects dissociated from cannabis consumption, cannabidiol has received significant attention. This study focuses on molecular modeling and the electronic properties of cannabidiol and cannabidiol-type compounds using chemical reactivity descriptors, aiming to understand the potential antioxidant properties. The radicals formed during free radical scavenging processes were evaluated in thermodynamic and electronic terms through the mechanisms of hydrogen atom transfer and one-electron transfer. The topological parameters showed that the interactions are of the closed-shell type and have a van der Waals character, except where the OH group rotation occurs, resulting in an H bond. Calculations of OH bond dissociation enthalpy and ionization potential showed that CBD-C5 has the best antioxidant potential among cannabidiol-type compounds.

Предмет ст. 305 КК України як обов’язкова ознака складу кримінального правопорушення

The subject matter of Article 305 of the Criminal Code of Ukraine has been considered as a mandatory element of the offense. The opinions of other authors regarding the definition of the concept of the subject matter of a criminal offense have been analyzed, and it has been concluded that the subject matter of a criminal offense should be understood as things of the material world that may be the subject of a criminal offense or are related to it. The subject matter of a criminal offense is an optional element of the offense. If the subject matter of a criminal offense is directly indicated in the disposition of the relevant article of the Special Part of the Criminal Code, it acquires the status of a mandatory element. Thus, the subject matter of Article 305 of the Criminal Code of Ukraine is narcotic substances, psychotropic substances, their analogues or precursors, or counterfeit medicinal products. Considering that this subject matter is directly mentioned in the article, it is a mandatory element of the offense, and the list of items mentioned in the article is exhaustive and cannot be expanded. In addition, the size and degree of social danger of a narcotic substance, psychotropic substance, their analogue or precursor, or counterfeit medicinal product affect the qualification, as the person who commits the criminal offense is held criminally responsible for the basic, qualified, or particularly qualified form of the offense. Therefore, after analyzing the subject matter of paragraphs 1, 2, and 3 of Article 305 of the Criminal Code of Ukraine, it has been concluded that there are no issues in the qualification of criminal offenses involving narcotic substances, psychotropic substances, or counterfeit medicinal products, as the legislator clearly differentiates the responsibility based on the size of the narcotic substance, psychotropic substance, their analogues or precursors, or counterfeit medicinal product (small, large, particularly large). However, regarding the qualification of criminal offenses involving particularly dangerous narcotic substances or psychotropic substances, there is a problem, as particularly dangerous narcotic substances and psychotropic substances are only the subject matter of paragraph 2 of Article 305 of the Criminal Code of Ukraine. Therefore, it is proposed to further differentiate the responsibility for criminal offenses involving particularly dangerous narcotic substances or psychotropic substances, taking into account their size (large, particularly large), and accordingly make changes to paragraph 3 of Article 305 of the Criminal Code of Ukraine, and present paragraph 4 in the following version: 3. Smuggling of narcotic substances, psychotropic substances, their analogues or precursors, or counterfeit medicinal products committed by an organized group, as well as if the subject of smuggling was narcotic substances, psychotropic substances, their analogues or precursors, or counterfeit medicinal products in particularly large quantities or particularly dangerous narcotic substances or psychotropic substances in large quantities, shall be punished... 4. Smuggling of particularly dangerous narcotic substances, psychotropic substances in particularly large quantities shall be punished...